Skip to main content
. 2020 Mar 6;10:313. doi: 10.3389/fonc.2020.00313

Table 2.

Top 10 adverse effects (all grade) associated with 2/1 vs. 4/2.

Adverse effects No. of studies 2/1 group (event/total) 4/2 group (event/total) RR (95% CI) P-value Heterogeneity
I2 (%) P-value
Leukopenia 4 86/135 111/135 0.86 [0.73, 1.00] 0.05 14 0.32
Thrombocytopenia/Platelet disorder 7 124/234 224/438 0.86 [0.70, 1.06] 0.15 64 0.01
Hand-foot syndrome 7 111/234 274/438 0.70 [0.60, 0.82] <0.0001 15 0.32
Neutropenia 5 59/146 106/168 0.62 [0.49, 0.79] <0.0001 30 0.22
Anemia 6 92/193 129/230 0.80 [0.67, 0.95] 0.01 40 0.14
Hypothyroidism 6 89/208 188/408 0.83 [0.69, 1.01] 0.06 5 0.39
Stomatitis/Mucositis 5 67/161 205/346 0.67 [0.54, 0.83] 0.0003 0 0.44
Hypertension 7 88/234 227/441 0.65 [0.53, 0.79] <0.0001 32 0.18
Fatigue 7 117/234 327/438 0.67 [0.59, 0.77] <0.00001 42 0.11
Abdominal pain/Diarrhea 7 85/234 218/438 0.67 [0.48, 0.92] 0.02 61 0.02

4/2, 4-weeks-on and 2-weeks-off; 2/1, 2-weeks-on and 1-week-off; RR, risk ratio; CI, confidence interval.